CorDynamics

Outsourcing Drug Development Research: Should We Be Afraid?

In Phoenix, at the American College of Toxicology annual meetings, we spoke with a number of industry decision-makers.

This year, the topic on everyone’s mind was—outsourcing. Pharma and biotech colleagues tell us of plans to outsource in almost every area of R&D including those that pertain to CorDynamics.

• Lead Optimization in Drug Discovery
• Safety Pharmacology
• Preclinical Toxicology
• Nonclinical Consulting

Some are wary at the speed and scope of predicted reliance on outsourcing. We get it. Before starting CorDynamics, my business partner Peter Senese and I were in their shoes, looking for quality contract research organizations to serve our R&D needs while still maintaining control of our projects, budgets and timelines.

Take an anesthetized study for instance. As a rule, these studies are conducted to obtain a complete cardiovascular assessment over escalating doses in the same animal – using multiple replicates. These results need to be turned around quickly, and oftentimes generated with limited compound supply. No problem, we get it – and have done it many times.

To us, “out” sourcing is a bit of misnomer as we think it insinuates clients are taken “out” of the loop. This couldn’t be farther than the truth. We have our technology and communication processes set up to ensure our clients feel they can access “their” data and, if need be, change course quickly. Our consulting services enable us to provide lead optimization strategies, regulatory compliance advice and FDA risk assessments.

Our philosophy has always been: We may be off-site, but we are always within reach.

It’s a model that works and one I’m excited to see the industry embrace.

Related Posts via Categories

• 5 Signs Drug Development Outsourcing is In
• Expanding Telemetry Widens the Drug Development Picture
• Preclinical Case Study: How to Investigate Hemodynamics and Cardiac Electrophysiology In Vivo
• 3 Big Lessons Learned from FDA Approval of Obesity Drug Lorcaserin
• FDA Denies Expanding Xarelto for Acute Coronary Syndrome
• Preclinical Services Published in British Journal of Pharmacology
• Tangible Ways to Work with Virtual Biotechs
• FDA Rejects Xarelto for Second Time in Less Than a Year
• Validated Anesthetized Model Screens Cardiovascular Effects Early
• How to Build a Relevant Bridge Between Ion Channel and In-Vivo Telemetry Studies: Langendorff Isolated Heart

• Tags:
•  American College of Toxicology,
•  CorDynamics,
•  Lead Optimization in Drug Discovery,
•  Nonclinical Consulting,
•  outsourcing,
•  Peter Senese,
•  Preclinical Toxicology,
•  R&D,
•  Safety Pharmacology